AirSeal is selected as a 2024 Arch Grants recipient, which includes a $75,000 non-dilutive cash award. - AirSeal CardioVascular

AirSeal is selected as a 2024 Arch Grants recipient, which includes a $75,000 non-dilutive cash award.

Releted Post

AirSeal is selected as a recipient of the first WashU Venture Network Follow-on Investments

April 12, 2025

Our co-founder, Dr. Zayed, was recently interviewed by KMOX Radio

April 1, 2025

AirSeal is awarded a co-investment of $500,000 from Missouri Technology Corporation (MTC)

November 12, 2024

AirSeal is honored to be selected as 1st first-place winner for the Biotech

June 1, 2024

AirSeal is selected as a 2024 Arch Grants recipient, which includes a $75,000 non-dilutive cash award.

https://olin.wustl.edu/about/news-and-media/news/2024/12/olin-emba-alums-arch-grants-healthcare-startups.php

AirSeal is advancing early, accurate diagnosis of cardiovascular diseases through innovative biomarker technology.

© 2023-2025 by AirSeal CardioVascular Inc. Designed & Developed by Steatech